Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (OTCQB: PRVCF) is a health sciences company that regularly issues news on its preventive and curative therapy programs, corporate developments and proposed corporate transactions. Company news provides insight into its research pipeline, including dual gene therapy for diabetes and obesity, the Sol-Gel nose-to-brain (N2B) delivery platform, Nature Identical™ peptide programs, nonaddictive analgesic peptide candidates and concussion-related therapeutic concepts.
Recent announcements have highlighted appointments of experienced scientific and industry advisors, such as corporate advisors and technology leaders who bring backgrounds in drug discovery, metabolic disease research, molecular genetics and clinical development. These updates help investors and observers understand how PreveCeutical is building expertise around its programs and advancing toward development and potential commercialization.
News releases also cover the evolution of the Sol-Gel N2B platform, including a program aimed at delivering dopamine and/or its precursor L-Dopa directly to the brain in the context of Parkinson’s disease. The company has described this platform as designed to bypass the blood-brain barrier, with the goal of improving drug bioavailability and reducing systemic side effects.
Another recurring theme in PreveCeutical’s news is its relationship with BioGene Therapeutics Inc., a wholly owned subsidiary focused on metabolic health and gene-based treatments. The company has announced a proposed plan of arrangement under which it intends to distribute up to 12,000,000 BioGene common shares to PreveCeutical shareholders, and meeting materials and court orders related to this arrangement have been reported in its news flow.
Investors and researchers following PRVCF news can use this page to review updates on research milestones, advisory and executive appointments, meeting dates, and the progress of the proposed BioGene share distribution, all drawn from official company announcements.
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board effective December 1, 2024. Dr. Gallagher brings over 25 years of experience in biotech and pharmaceutical investments, having served as Managing Partner at Trekk Venture Partners and Partner at Abingworth. His notable achievements include overseeing Sirtris Pharmaceuticals' $720 million acquisition by GlaxoSmithKline and contributing to Translate Bio's $3.2 billion acquisition by Sanofi.
Dr. Gallagher holds a Ph.D. in Organic Chemistry from the University of Michigan and has served as Chairman of eFFECTOR Therapeutics. His expertise spans venture capital, strategic investments, and corporate development within the biotech sector.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Stephen Glover as an independent director effective November 30, 2024. The company's CEO, Stephen Van Deventer, highlighted Glover's expertise in biopharma, corporate strategy, commercialization, and financial management, noting his track record in building and transforming organizations aligns with BioGene's mission to advance groundbreaking therapies.
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Deepak Sampath as an independent director effective November 21, 2024. Dr. Sampath brings over 25 years of experience in molecular biology, pharmacology, and drug development. Currently serving as Senior Vice President and Head of Research at Ultragenyx, he has contributed significantly to oncological treatments, including the FDA approval of venetoclax for CLL/SLL. His expertise spans protein biologics, nucleic acids, and gene therapies, with 108 published articles and involvement in 32 patents/applications. At Ultragenyx, he leads research in genetic conditions across neurological, metabolic, bone, and muscular diseases.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Professor Mirela Delibegovic, FRSE to its Scientific Advisory Board effective November 19, 2024. The company, which focuses on developing preventive and curative therapies using organic and nature-identical products, expects to benefit from Delibegovic's expertise in obesity and diabetes physiology and signaling research to advance their therapeutic programs in metabolic health.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced two key appointments at its subsidiary BioGene Therapeutics Inc. Dr. Linnea Olofsson joins as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer, effective November 16, 2024. Dr. Parekh brings over two decades of experience in pharmaceutical chemistry and drug/gene delivery systems from The University of Queensland's School of Pharmacy. Dr. Olofsson contributes expertise in biophysics, oncology, molecular biology, and CRISPR/Cas9 gene editing. These appointments aim to advance BioGene's scientific initiatives and therapeutic applications development.
PreveCeutical Medical has completed the intellectual property asset sale transaction with its subsidiary BioGene Therapeutics. The transaction, valued at USD$1,353,227, involves PreveCeutical and PreveCeutical Australia selling certain intellectual property assets to BioGene. The payment structure includes USD$500,000 in cash to be paid within 24 months and 16,000,000 common shares of BioGene at USD$0.0533 per share. PreveCeutical plans to distribute a portion of these shares to its shareholders at a future date.
PreveCeutical Medical has announced the appointment of Dr. Mariya Georgieva as President of its wholly-owned subsidiary BioGene Therapeutics, effective November 11, 2024. Dr. Georgieva joins from AstraZeneca where she served as Director of Diagnostic Alliances in Precision Medicine R&D since 2019. Previously, she headed applications and business development at Oxford-based ONI. She holds a PhD in Biomedical Science from the University of Montpellier, specializing in single-molecule fluorescence tools for studying epigenetic alterations.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has signed a definitive agreement to sell intellectual property assets to BioGene Therapeutics, its wholly owned subsidiary, for USD$1,353,227. The deal includes IP from UniQuest's research program and bio-responsive gene carrier systems for siRNA delivery in diabetes and obesity treatment. The purchase price consists of USD$500,000 in cash (payable within 24 months) and 16,000,000 common shares of BioGene at USD$0.0533 per share. PreveCeutical plans to distribute approximately 75% of the consideration shares to its shareholders on a pro-rata basis, with details and record date to be announced.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has engaged Phoenix Corporate Finance Inc. to provide strategic and corporate advisory services for potential future transactions. Phoenix, based in Toronto, will advise on potential strategic transactions, including asset acquisitions or dispositions. As compensation, PreveCeutical will pay Phoenix $30,000 plus applicable taxes.
Stephen Van Deventer, Chairman and CEO of PreveCeutical, stated that as the company transitions from R&D to the clinical phase, they believe strategic partnerships and a new approach to their four research programs will be necessary. The company plans to allocate additional resources and talent to each program, specific to their respective medical fields.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has entered into a Marketing Service Agreement with Outside the Box Capital (OTB) effective September 1, 2024. The agreement, running from September 3, 2024, to March 3, 2025, involves OTB providing various marketing and distribution services to enhance PreveCeutical's visibility and investor engagement.
As compensation, PreveCeutical will pay OTB a cash fee of $150,000 and grant 5,000,000 share purchase options at $0.05 per share, valid for 12 months. The services include content planning for PreveCeutical's YouTube channel, establishing a project ambassador, assisting with social media engagement, and promoting company insights across various platforms to attract new clients and interested parties.